PCSA logo

Processa Pharmaceuticals (PCSA) Cash And Cash Equivalents

Annual Cash & Cash Equivalents

$4.71 M
-$1.80 M-27.64%

31 December 2023

PCSA Cash And Cash Equivalents Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Cash And Cash Equivalents

$2.89 M
-$2.68 M-48.10%

30 September 2024

PCSA Quarterly Cash And Cash Equivalents Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PCSA Cash And Cash Equivalents Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-27.6%-57.9%
3 y3 years-69.5%-84.9%
5 y5 years+170.3%+473.4%

PCSA Cash And Cash Equivalents High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 years-71.5%at low-84.9%at low
5 y5 years-71.5%+580.6%-87.5%+1932.0%
alltimeall time-71.5%-87.5%

Processa Pharmaceuticals Cash And Cash Equivalents History

DateAnnualQuarterly
Sept 2024
-
$2.89 M(-48.1%)
June 2024
-
$5.57 M(-37.5%)
Mar 2024
-
$8.92 M(+89.5%)
Dec 2023
$4.71 M(-27.6%)
$4.71 M(-31.4%)
Sept 2023
-
$6.86 M(-20.9%)
June 2023
-
$8.68 M(-19.2%)
Mar 2023
-
$10.74 M(+65.2%)
Dec 2022
$6.50 M(-60.6%)
$6.50 M(-28.2%)
Sept 2022
-
$9.05 M(-24.9%)
June 2022
-
$12.06 M(-16.2%)
Mar 2022
-
$14.39 M(-12.7%)
Dec 2021
$16.50 M(+7.0%)
$16.50 M(-13.6%)
Sept 2021
-
$19.09 M(-8.3%)
June 2021
-
$20.83 M(-9.6%)
Mar 2021
-
$23.05 M(+49.5%)
Dec 2020
$15.42 M(+2129.4%)
$15.42 M(+4637.6%)
Sept 2020
-
$325.40 K(-28.1%)
June 2020
-
$452.70 K(+218.1%)
Mar 2020
-
$142.30 K(-79.4%)
Dec 2019
$691.50 K(-60.3%)
$691.50 K(+37.1%)
Sept 2019
-
$504.30 K(-30.2%)
June 2019
-
$722.00 K(-42.2%)
Mar 2019
-
$1.25 M(-28.3%)
Dec 2018
$1.74 M
$1.74 M(-28.2%)
Sept 2018
-
$2.42 M(-15.0%)
DateAnnualQuarterly
June 2018
-
$2.85 M(+60.4%)
Mar 2018
-
$1.78 M(-37.6%)
Dec 2017
$2.85 M(>+9900.0%)
$2.85 M(+3446.0%)
Sept 2017
-
$80.30 K(+4126.3%)
June 2017
-
$1900.00(+18.8%)
Mar 2017
-
$1600.00(-50.0%)
Dec 2016
$3200.00(+52.4%)
$3200.00(-52.2%)
Sept 2016
-
$6700.00(-55.0%)
June 2016
-
$14.90 K(+520.8%)
Mar 2016
-
$2400.00(+14.3%)
Dec 2015
$2100.00(>+9900.0%)
$2100.00(-86.1%)
Sept 2015
-
$15.10 K(-0.7%)
June 2015
-
$15.20 K(-63.6%)
Mar 2015
-
$41.80 K(>+9900.0%)
Dec 2014
$0.00(-100.0%)
$0.00(-100.0%)
Sept 2014
-
$55.70 K(+39.6%)
June 2014
-
$39.90 K(-51.5%)
Mar 2014
-
$82.20 K(-56.0%)
Dec 2013
$186.90 K(-81.7%)
$186.90 K(-81.3%)
Sept 2013
-
$1.00 M(+59.1%)
June 2013
-
$629.80 K(+49.4%)
Mar 2013
-
$421.50 K(-58.7%)
Dec 2012
$1.02 M(-63.5%)
$1.02 M(-26.6%)
Sept 2012
-
$1.39 M
Dec 2011
$2.79 M
-

FAQ

  • What is Processa Pharmaceuticals annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Processa Pharmaceuticals?
  • What is Processa Pharmaceuticals annual cash & cash equivalents year-on-year change?
  • What is Processa Pharmaceuticals quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Processa Pharmaceuticals?
  • What is Processa Pharmaceuticals quarterly cash and cash equivalents year-on-year change?

What is Processa Pharmaceuticals annual cash & cash equivalents?

The current annual cash & cash equivalents of PCSA is $4.71 M

What is the all time high annual cash & cash equivalents for Processa Pharmaceuticals?

Processa Pharmaceuticals all-time high annual cash & cash equivalents is $16.50 M

What is Processa Pharmaceuticals annual cash & cash equivalents year-on-year change?

Over the past year, PCSA annual cash & cash equivalents has changed by -$1.80 M (-27.64%)

What is Processa Pharmaceuticals quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of PCSA is $2.89 M

What is the all time high quarterly cash and cash equivalents for Processa Pharmaceuticals?

Processa Pharmaceuticals all-time high quarterly cash and cash equivalents is $23.05 M

What is Processa Pharmaceuticals quarterly cash and cash equivalents year-on-year change?

Over the past year, PCSA quarterly cash and cash equivalents has changed by -$3.97 M (-57.85%)